Ingevity
NGVT · Specialty Chemicals
$69.64
0.3%Sensient Technologies
SXT · Specialty Chemicals
$132.65
1.3%The short version
- Sensient Technologies is the larger business, with $1.6B of revenue in fiscal 2025 against $1.2B for Ingevity.
- Sensient Technologies grew revenue faster (3.5%, against −2.7%).
- Ingevity kept more of each dollar of sales as operating profit (35.9% operating margin, against 12.9% operating margin).
- Ingevity turned more of its sales into free cash flow (23.4% FCF margin, against 2.4% FCF margin).
- Ingevity earned a higher return on the capital invested in it (24.6%, against 8.9%).
- Investors pay more for each dollar of Ingevity’s earnings: a P/E of 46.4x against 35.8x for Sensient Technologies.
| Latest fiscal year | NGVT · FY25 | SXT · FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $5.7B |
| Revenue | $1.2B | $1.6B |
| Free cash flow | $274M | $38.4M |
| Net income | −$167M | $135M |
| Growth | ||
| Revenue growth | −2.7% | 3.5% |
| 5-year growth | −0.8% | 3.9% |
| Share count change | −0.3% | 0.5% |
| Profitability | ||
| Gross margin | 39.5% | 33.5% |
| Operating margin | 35.9% | 12.9% |
| Net margin | −14.3% | 8.3% |
| FCF margin | 23.4% | 2.4% |
| Return on capital | 24.6% | 8.9% |
| Return on equity | −148.6% | 11.9% |
| Balance sheet | ||
| Net debt | $1.1B | $673M |
| Net debt / EBITDA | 2.2x | 2.5x |
| Dividends and buybacks | $56.3M | $69.6M |
| Valuation & quality | ||
| P/E | 46.4x | 35.8x |
| Piotroski F-score | 6 | 6 |
FY16
NGVT $908M
SXT $1.4B
FY17
NGVT $972M
SXT $1.4B
FY18
NGVT $1.1B
SXT $1.4B
FY19
NGVT $1.3B
SXT $1.3B
FY20
NGVT $1.2B
SXT $1.3B
FY21
NGVT $1.4B
SXT $1.4B
FY22
NGVT $1.7B
SXT $1.4B
FY23
NGVT $1.2B
SXT $1.5B
FY24
NGVT $1.2B
SXT $1.6B
FY25
NGVT $1.2B
SXT $1.6B
NGVT
SXT
FY16
NGVT 18.0%
SXT 13.1%
FY17
NGVT 25.0%
SXT 12.0%
FY18
NGVT 28.3%
SXT 14.7%
FY19
NGVT 30.7%
SXT 9.2%
FY20
NGVT 32.7%
SXT 11.5%
FY21
NGVT 30.3%
SXT 12.3%
FY22
NGVT 27.1%
SXT 13.7%
FY23
NGVT 34.8%
SXT 10.6%
FY24
NGVT 35.5%
SXT 12.3%
FY25
NGVT 35.9%
SXT 12.9%
NGVT
SXT
FY16
NGVT $71.2M
SXT $102M
FY17
NGVT $122M
SXT −$20.0M
FY18
NGVT $158M
SXT $32.8M
FY19
NGVT $161M
SXT $138M
FY20
NGVT $270M
SXT $167M
FY21
NGVT $190M
SXT $84.4M
FY22
NGVT $171M
SXT −$67.3M
FY23
NGVT $95.3M
SXT $81.8M
FY24
NGVT $51.0M
SXT $97.9M
FY25
NGVT $274M
SXT $38.4M
NGVT
SXT
FY16
NGVT 14.4%
SXT 9.5%
FY17
NGVT 32.6%
SXT 7.1%
FY18
NGVT 31.7%
SXT 11.8%
FY19
NGVT 23.4%
SXT 6.5%
FY20
NGVT 18.0%
SXT 8.3%
FY21
NGVT 18.3%
SXT 8.9%
FY22
NGVT 18.9%
SXT 10.0%
FY23
NGVT 16.8%
SXT 6.8%
FY24
NGVT 19.1%
SXT 8.8%
FY25
NGVT 24.6%
SXT 8.9%
NGVT
SXT
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.